Positive Topline Results in 5-MeO-DMT Study for Alcohol Use Disorder
Atai Life Sciences announced positive topline results from a Phase 2a study of BPL-003, a synthetic intranasal 5-MeO-DMT formulation,...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Atai Life Sciences announced positive topline results from a Phase 2a study of BPL-003, a synthetic intranasal 5-MeO-DMT formulation,...
Data minimization is one of the fundamental principles of the General Data Protection Regulation (GDPR), aimed at ensuring that...
In this interview, we sit down with Mario Marcondes from Nektar Therapeutics to explore the advancements and potential of...
At the DPHARM conference, Eisai Inc. showcased their groundbreaking use of Bayesian methods to achieve accelerated approval for their...
In the fast-evolving world of clinical trials, GDPR compliance is more than a legal obligation—it’s a pillar of trust,...
Oncomatryx, a biopharmaceutical company developing antibody-drug conjugates (ADCs), secured €25 million to advance clinical trials of OMTX705, a first-in-class...
LIB Therapeutics‘ Phase 3 LIBerate-HoFH study results for lerodalcibep, a novel PCSK9 inhibitor, in patients with homozygous familial hypercholesterolemia...
Quince Therapeutics announced the publication of long-term safety data from Ataxia-Telangiectasia (A-T) patients treated with EryDex for at least...
ILiAD Biotechnologies and hVIVO will collaborate on a Phase 3 human challenge trial for ILiAD’s next-generation intranasal pertussis vaccine,...
RenovoRx announced promising pharmacokinetic data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial, investigating its Trans-Arterial...